Primary hyperparathyroidism: Insights for the next millenium

Clinical Laboratory

Volumn 45, Issue 7-8, 1999, Pages 403-407

  Bilezikian, John P ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; LITHIUM; PARATHYROID HORMONE; THIAZIDE DIURETIC AGENT;

BONE METASTASIS; CHEMOLUMINESCENCE; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; FUTUROLOGY; HUMAN; HYPERCALCEMIA; IMMUNOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; KIDNEY FAILURE; PRIMARY HYPERPARATHYROIDISM; QUANTITATIVE ASSAY; REVIEW; SCREENING TEST; SYMPTOM;

EID: 0032768275     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Bilezikian JP, Silverberg SJ, Gartenberg F, Kim TS, Jacobs TP, Siris ES, Shane E: Clinical presentation of primary hyperparathyroidism. In: The Parathyroids. (Bilezikian JP, ed), New York: Raven; 1994:457-470.
2. Silverberg SJ, Fitzpatrick LA, Bilezikian JP: Hyperparathyroidism, In Becker KL (ed): Principles and Practice of Endocrinology and Metabolism, 2nd ed, Philadelphia, JB Lippincott, 1995, 512-519.
3. Goltzman D, Henderson JE: Expression of PTHrP in Disease. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA) Academic Press, San Diego, 809-826, 1996.
4. LePage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P. A non(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurement in uremic samples. Clin Chem 44:805-809, 1998.
5. Heath H III, Hodgson SF, Kennedy MA: Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Eng J Med 1980;302: 189.
6. Bilezikian JP and Silverberg SJ: Asymptomatic primary hyperparathyroidism. In. Parathyroid Diseases: From the Gene to the Cure (Brandi ML, ed) Societa Editrice Europea di Nicodemo Maggiulli & Co., Firenze, Italy, 73-90, 1997.
7. Fitzpatrick LA. Acute primary hyperparathyroidism. In: The Parathyroids (Bilezikian JP, Marcus R, Levine MA) Raven Press, New York. 583-589, 1994.
8. Hannarayan DV, Gupta N, Kochupillai N: Vitamin D status in primary hyperparathyroidism in India Clin Endocrinol 1995,43.351-358.
9. Bilezikian JP, Silverberg SJ Usefulness of bone mass measurements in primary hyperparathyroidism. Current Opinion in Endocrinol & Diabetes 1996;3:514-520.
10. Luong KVQ, Nguyen LTH: Coexisting hyperthyroidism and primary hyperparathyroidism with vitamin D-deficient osteomalacia in a vietnamese immigrant. Endocrine Practice 1996;2:250-254.
11. Woodhouse NJY, Doyle FH, Joplin GF: Vitamin D deficiency and primary hyperparathyroidism. Lancet 1971 ;7:283-287.
12. Lumb GA, Stanbury SW: Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974;56:833-839.
13. Takemia T, Sato K, Miyata M et al: A patient with primary hyperparathyroidism associated with osteomalacia. Endocrine J 1993;40:121-126.
14. Blumsohn A, Eastell R: Age-related factors in osteoporosis. In Osteoporosis: etiology, diagnosis, and management (Riggs BL and Melton LJ III, eds). Philadelphia, Lippincott-Raven, 161-182, 1995.
15. Thomas MK, Lloyd-Jones D, Thadhani RJ et al. Hypovitaminosis D in medical inpatients N Eng J Med 1998; 338: 778-783.
16. Seibel MJ, Robins SP, Bilezikian JP: Biochemical markers of bone resorption. Principles and Practice of Endocrinology and Metabolism, 2nd ed, Philadelphia, JB Lippincott, 1995, 498-508.
17. Broadus AE, Horst RL, Lang R, Littledike ET, Rasmussen H: The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism. N Eng J Med 1980;302:421.
18. Silverberg SJ, Shane E, de Ia Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Sins ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP: Skeletal disease in primary hyperparathyroidism. J Bone Min Res 1989;4:283-291.
19. 99mTc sestamibi scanning and intraoperative quick parathormone assay. Surgery 122: 1107-1116, 1997
20. Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference Statement. Ann Intern Med 1991;114:593-597.
21. Stock JL, Marcus R: Medical management of primary hyperparathyroidism. In The Parathyroids Edited by Bilezikian JP. New York: Raven; 1994:519-529.
22. Locker FG, Silverberg SJ, Bilezikian JP: Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997; 102:543-550.
23. Marcas R, Madvig P, Crim M, Pont A, Kosek J: Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Int Med 1984; 100:633.
24. Selby PL, Peacock M: Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Eng J Med 1986,314:1481
25. McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Min Res 1994;9:509-514.
26. Kaplan RA, Geho WB, Poindexter C, Haussler M, Dietz GW, Pak CYC. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol 1977; 17:410-419.
27. Adami S, Mian M, Bertoldo F et al. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment. Clin Endocrinol 1990; 33: 391-397.
28. Brown EM, Haris HW, Vassilev PM, Hebert SC: The biology of the extracellular calcium-sensing receptor. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA) Academic Press, San Diego, 243-262, 1996.
29. Nemeth EF. Calcium receptors as novel drug targets. In: Principles of Bone Biology (Bilezikian JP, Raisz LR, Rodan GA) Academic Press, San Diego, 1019-1036, 1996.
30. Silverberg SJ, Bone HG III, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Sanguinetti EL, Bilezikian JP: Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in primary hyperparathyroidism. N Eng J Med 1997; 337: 1506-1510.
31. Christensson TAT. Primary hyperparathyroidism-pathogenesis, incidence and natural history. Prog Surg 1986; 18:34-44.
32. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for a biphasic disease course. J Clin Endocrinol Metab 1988;67: 1294-1298.
33. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, Bilezikian JP. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab 1995;80:723-728.